The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …

Parkinson's disease affects 5 million people worldwide, but the molecular mechanisms
underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis …

Profound neuronal dysfunction in the entorhinal cortex contributes to early loss of short-term
memory in Alzheimer's disease,,. Here we show broad neuroprotective effects of entorhinal …

Until recently, the brain was studied almost exclusively by neuroscientists and the immune
system by immunologists, fuelling the notion that these systems represented two isolated …

A molecular test for Alzheimer's disease could lead to better treatment and therapies. We
found 18 signaling proteins in blood plasma that can be used to classify blinded samples …

The biologic underpinnings of posttraumatic stress disorder (PTSD) have not been fully
elucidated. Previous work suggests that alterations in the immune system are characteristic …

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the
characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting …

Developing effective treatments for neurodegenerative diseases is one of the greatest
medical challenges of the 21st century. Although many of these clinical entities have been …